Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

Schrödinger announced it will discontinue clinical development of the CDC7 inhibitor SGR-2921 for acute myeloid leukemia (AML) and myelodysplastic syndromes following two patient deaths in an ...

IO Biotech plans to meet with the FDA this fall to discuss the data from the phase 3 trial of Cylembio and determine next ...

Intervention/Treatment: The study tests two treatment regimens: one with durvalumab and tremelimumab, and the other with pembrolizumab, both combined with platinum-based chemotherapy. These drugs aim ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Study Overview: Pfizer Inc. is conducting a Phase 1 open-label study ...